2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics

May 2017



Hotel Novotel Barcelona City

Avenida Diagonal 201, 08018

About Summit

This premier B2B event provides the appropriate platform to engage and discuss ideas with your peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on current challenges, best practices and the inside view of the future of ADCs. We will discuss key findings, including critical insights, as well as recommendations for driving efficient strategies in the ADCs landscape.

Who Should Attend

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders, Managers, Clinical Development Experts and Scientists specialising in:

  • Antibody & Biologics Discovery /Development
  • Protein Engineering
  • Medicinal Chemistry
  • Bioconjugates
  • Monoclonal antibodies (mAbs)
  • Tubulysins
  • PBD-dimers
  • Topoisomerase inhibitors
  • Small-molecule drug conjugates
  • Nanoparticles/Nanobodies
  • PKPD
  • Toxicology
  • Bioanalysis
  • Oncology
  • Antibody-based therapeutics
  • Immunotherapeutics
  • Manufacturing/CMC
  • Molecular Biology
  • Antibody-drug conjugates (ADCs)
  • Immunoconjugates
  • Maytansine
  • Duocarmycin
  • α-amanitin
  • Marine-based cytotoxins
  • Peptide-drug conjugates
  • Diabodies/Minibodies
  • ADME
  • Analytical & Formulation
  • Cancer
  • Hematology
  • Biotherapeutics
  • Chemotherapeutics
Key Practical Learning Points of the Summit

360° view of Antibody Drug Conjugates (ADCs) from key industry players to leverage your business and scientific practice adoption
Emerging discoveries, cutting-edge knowledge, tools, methods, and technologies to design safe and efficient next-generation ADCs
Strategies to improve target selection, increase cytotoxic potency, explore developments of novel linker chemistry, applied to next-generation payloads, discover emerging conjugation methods, accelerate preclinical development, and successfully translate into the clinic
Approaches to improve the ADC therapeutic risk-benefit ratio, to create new paradigm for novel anti-cancer chemotherapy, to expand the application of ADCs beyond oncology and haematology
Dr. Eric Valeur

Associate Director New Modalities & Lead Generation

AstraZeneca, Sweden

Dr. Björn Hock

Senior Director, Global Head ADCs & Targeted NBE Therapeutics

Merck KGaA, Germany

Dr. Pernille Hemmingsen

Associate Director CMC Project Manager

Genmab, Denmark

Dr. Ling Xu

Bioanalysis of Small Molecules & Antibody Drug Conjugates

Mersana Therapeutics, Inc. (represented Millennium Pharmaceuticals, Inc., subsidiary of Takeda), US

Dr. Charlotte Hagman

Chemical Biology / Biochemistry / Analytical Chemistry

Novartis AG, Switzerland

Dr. Berthold Boedeker

Global Biological Development WUP

Bayer AG, Germany

Dr. Alex Lazar

Director Analytical & Pharmaceutical Sciences

ImmunoGen, Inc., US

Dr. Markus Walles

Team Lead Metabolism DMPK/IDD

Novartis AG, Switzerland

Dr. Cecilia Simonelli

Head of Corporate Therapeutic Area: Oncology, Immunology & Anti-Infective

Menarini-Ricerch Menarini Group, Italy

Ulrich Rümenapp

Head of Launch Preparation and Coordination

Bayer AG

Stephan Schmidt

Sr. Vice President Process Science and Production

Rentschler Biotechnologie GmbH

Lucia D'Amico

Department of Biomedicine

University Hospital Basel

Floris van Delft

Founder and CSO & Prof. of Bioconjugate Chemistry

SynAffix & Wageningen University

Christian Rohlff


Oxford BioTherapeutics

Ulf Grawunder


NBE-Therapeutics Ltd.

Laurent Ducry

Head of Commercial Development for Bioconjugates


Andrew Kyle

Team Leader


Jens Lohrmann

Translational Clinical Oncology

Novartis AG

Chrisof Seidl

Department of Nuclear Medicine Department of Obstetrics and Gynecology

Technische Universität München



Sponsors and Partners






Media partner

Media partner

Media partner

Media partner

Media partner

Media partner